Cancer Immunotherapy Market – Top Players and Business Growth Strategies

According to research report Cancer Immunotherapy Market
is expected to reach USD 119.39 Billion by 2021 from USD 61.97 Billion
in 2016, at a CAGR of 14.0% from 2016 to 2021. This report provides a
detailed overview of the major drivers, restraints, challenges,
opportunities, current market trends, and strategies impacting the
global cancer immunotherapy market along with the estimates and
forecasts of the revenue and market share analysis.

Cancer immunotherapy drugs are designed to alter or boost the body’s natural
immune response to fight cancer this market is research-driven with a
high degree of dependence on the discovery of molecules that can
generate an immune response against various indications.

The cancer immunotherapy market has been segmented, on the basis of product
into monoclonal antibodies, immunomodulators, vaccines, and check point
inhibitors. The check point inhibitors segment is estimated to witness
the highest CAGR during 2016-2021. The high growth can be attributed to
the benefits offered by this therapeutic drug.

The global cancer immunotherapy market is consolidated in nature, marked with the presence
of a few large players. The prominent players in this market are Amgen
(U.S.), AstraZeneca (U.K.), F. Hoffmann-La Roche Ltd(Switzerland), Bayer
AG (Germany), Bristol-Myers Squibb (U.S.), Eli Lilly and Company
(U.S.), Janssen Global Services, LLC (Belgium), Merck (U.S.), Novartis
(Switzerland), and Pfizer (U.S.).

Amgen was the largest player in the global cancer immunotherapy market in 2015. The company has a
strong presence in the U.S., Europe, Asia-Pacific, the Middle East, and
Africa. In order to sustain its foothold and further increase its share
in the market, the company pursues the strategy of new product launches,
which significantly impacts the companys customer base.

In 2015, F. Hoffmann-La Roche AG accounted for the second-largest share in the
cancer immunotherapy market. The company focuses on developing
innovative products to provide efficient solutions to its customers.

Bristol-Myers Squibb (BMS) held the third position in the cancer immunotherapy market
in 2015. The company has a first-mover advantage as two of its drugs
(Opdivo and Yervoy) have already been approved and commercialized. These
products recently received an approval of oncolytic virus Imlygic and
cancer vaccine Empliciti from the U.S. FDA.

The key strategies followed by most companies in the cancer immunotherapy market are new
products launches and approvals; expansions; acquisitions; and
partnerships, agreements, and collaborations. The strategy of new
products launches and approvals accounted for the largest share of the
overall growth strategies mapped from 2013 to 2016. Companies seek new
and advanced product approvals to strengthen their product portfolios
and cater to the unmet needs of their customers. Some of the leading
players that adopted this strategy include Amgen (U.S.), F. Hoffmann-La
Roche Ltd. (Switzerland), Bristol-Myers Squibb (U.S.), and Merck (U.S.).